Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 413

1.

Small bowel polyp resection using device-assisted enteroscopy in Peutz-Jeghers Syndrome: Results of a specialised tertiary care centre.

Perrod G, Samaha E, Perez-Cuadrado-Robles E, Berger A, Benosman H, Khater S, Vienne A, Cuenod CA, Zaanan A, Laurent-Puig P, Rahmi G, Cellier C.

United European Gastroenterol J. 2020 Mar;8(2):204-210. doi: 10.1177/2050640619874525. Epub 2019 Sep 10.

PMID:
32213068
2.

Loss of SMARCB1 expression in colon carcinoma.

Melloul S, Mosnier JF, Masliah-Planchon J, Lepage C, Le Malicot K, Gornet JM, Edeline J, Dansette D, Texereau P, Delattre O, Laurent Puig P, Taieb J, Emile JF.

Cancer Biomark. 2020;27(3):399-406. doi: 10.3233/CBM-190287.

PMID:
32083567
3.

[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].

Koual M, Perkins G, Delanoy N, Crespel C, Medioni J, Nguyen-Xuan HT, Douay-Hauser N, Blons H, Le Frère-Belda MA, Molière D, Achen G, Nos C, Balaya V, Montero R, Laurent-Puig P, Bats AS.

Ann Pathol. 2020 Feb 8. pii: S0242-6498(20)30026-2. doi: 10.1016/j.annpat.2020.01.004. [Epub ahead of print] French.

PMID:
32046878
4.

Role of GSTM1 and GSTT1 genotypes in differentiated thyroid cancer and interaction with lifestyle factors: Results from case-control studies in France and New Caledonia.

Tcheandjieu C, Cordina-Duverger E, Mulot C, Baron-Dubourdieu D, Guizard AV, Schvartz C, Laurent-Puig P, Guénel P, Truong T.

PLoS One. 2020 Jan 30;15(1):e0228187. doi: 10.1371/journal.pone.0228187. eCollection 2020.

5.

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.

Randrian V, Adenis A, Desrame J, Barbier E, Di Fiore F, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Breysacher G, Roquin G, Louafi S, Lopez A, Louvet C, Borg C, Metges JP, Faroux R, Gaba L, Manfredi S, Tougeron D.

Dig Liver Dis. 2020 Mar;52(3):347-350. doi: 10.1016/j.dld.2019.11.014. Epub 2019 Dec 30.

PMID:
31899122
6.

HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.

Veyer D, Wack M, Mandavit M, Garrigou S, Hans S, Bonfils P, Tartour E, Bélec L, Wang-Renault SF, Laurent-Puig P, Mirghani H, Rance B, Taly V, Badoual C, Péré H.

Int J Cancer. 2019 Nov 22. doi: 10.1002/ijc.32804. [Epub ahead of print]

PMID:
31756275
7.

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status.

Raffenne J, Nicolle R, Puleo F, Le Corre D, Boyez C, Marechal R, Emile JF, Demetter P, Bardier A, Laurent-Puig P, de Mestier L, Paradis V, Couvelard A, VanLathem JL, MacKey JR, Bachet JB, Svrcek M, Cros J.

Cancers (Basel). 2019 Nov 18;11(11). pii: E1808. doi: 10.3390/cancers11111808.

8.

Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Lee JS, Rhee TM, Pietrasz D, Bachet JB, Laurent-Puig P, Kong SY, Takai E, Yachida S, Shibata T, Lee JW, Park HC, Zang DY, Jeon K, Lee J, Kim M, Kim HS, Kang HJ, Lee YK.

Sci Rep. 2019 Nov 18;9(1):16971. doi: 10.1038/s41598-019-53271-6.

9.

Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.

Moati E, Blons H, Taly V, Garlan F, Wang-Renault SF, Pietrasz D, Didelot A, Garrigou S, Saint A, Pernot S, Taieb J, Laurent-Puig P, Zaanan A.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32657. [Epub ahead of print]

PMID:
31472013
10.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S.

EBioMedicine. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

11.

Ampullary carcinoma prognostic markers.

Perkins G, Laurent-Puig P, Taieb J.

Oncotarget. 2019 Jul 16;10(44):4509-4510. doi: 10.18632/oncotarget.27067. eCollection 2019 Jul 16. No abstract available.

12.

Exploring the best treatment options for BRAF-mutant metastatic colon cancer.

Taieb J, Lapeyre-Prost A, Laurent Puig P, Zaanan A.

Br J Cancer. 2019 Sep;121(6):434-442. doi: 10.1038/s41416-019-0526-2. Epub 2019 Jul 29. Review.

PMID:
31353365
13.

The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer.

Taieb J, Jung A, Sartore-Bianchi A, Peeters M, Seligmann J, Zaanan A, Burdon P, Montagut C, Laurent-Puig P.

Drugs. 2019 Sep;79(13):1375-1394. doi: 10.1007/s40265-019-01165-2. Review.

14.

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study.

Mas L, Bachet JB, Taly V, Bouché O, Taieb J, Cohen R, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Laurent-Puig P.

Cancers (Basel). 2019 Jul 17;11(7). pii: E998. doi: 10.3390/cancers11070998.

15.

Molecular targeted therapy of BRAF-mutant colorectal cancer.

Ducreux M, Chamseddine A, Laurent-Puig P, Smolenschi C, Hollebecque A, Dartigues P, Samallin E, Boige V, Malka D, Gelli M.

Ther Adv Med Oncol. 2019 Jun 18;11:1758835919856494. doi: 10.1177/1758835919856494. eCollection 2019. Review.

16.

Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.

Bruzzi M, Auclin E, Lo Dico R, Voron T, Karoui M, Espin E, Cianchi F, Weitz J, Buggenhout A, Malafosse R, Denimal F, Le Malicot K, Vernerey D, Douard R, Emile JF, Lepage C, Laurent-Puig P, Taieb J.

Ann Surg Oncol. 2019 Oct;26(11):3561-3567. doi: 10.1245/s10434-019-07513-6. Epub 2019 Jun 17.

PMID:
31209667
17.

NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.

Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E.

Cancer Med. 2019 Aug;8(9):4330-4337. doi: 10.1002/cam4.2175. Epub 2019 Jun 14.

18.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
19.

Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.

Boige V, Mollevi C, Gourgou S, Azria D, Seitz JF, Vincent M, Bigot L, Juzyna B, Miran I, Gerard JP, Laurent-Puig P.

Int J Cancer. 2019 Dec 1;145(11):3163-3172. doi: 10.1002/ijc.32417. Epub 2019 May 31.

PMID:
31107542
20.

A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic.

Salvucci M, Rahman A, Resler AJ, Udupi GM, McNamara DA, Kay EW, Laurent-Puig P, Longley DB, Johnston PG, Lawler M, Wilson R, Salto-Tellez M, Van Schaeybroeck S, Rafferty M, Gallagher WM, Rehm M, Prehn JHM.

JCO Clin Cancer Inform. 2019 Apr;3:1-17. doi: 10.1200/CCI.18.00056.

21.

DNAshell Protects DNA Stored at Room Temperature for Downstream Next-Generation Sequencing Studies.

Washetine K, Heeke S, Ribeyre C, Bourreau C, Normand C, Blons H, Laurent-Puig P, Mulot C, Clermont D, David M, Clément B, Dagher G, Hofman P.

Biopreserv Biobank. 2019 Aug;17(4):352-354. doi: 10.1089/bio.2018.0129. Epub 2019 Mar 26. No abstract available.

PMID:
30912674
22.

The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.

Lutz MP, Zalcberg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, Lordick F, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F.

Eur J Cancer. 2019 May;112:1-8. doi: 10.1016/j.ejca.2019.01.106. Epub 2019 Mar 15. Review.

PMID:
30878666
23.

Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.

Perkins G, Svrcek M, Bouchet-Doumenq C, Voron T, Colussi O, Debove C, Merabtene F, Dumont S, Sauvanet A, Hammel P, Cros J, André T, Bachet JB, Bardier A, Douard R, Meatchi T, Peschaud F, Emile JF, Cojean-Zelek I, Laurent-Puig P, Taieb J.

Br J Cancer. 2019 Apr;120(7):697-702. doi: 10.1038/s41416-019-0415-8. Epub 2019 Mar 6.

24.

[Tumor banks and complex data management: Current and future challenges].

Hofman P, Dagher G, Laurent-Puig P, Marquette CH, Barlesi F, Bibeau F, Clément B.

Ann Pathol. 2019 Apr;39(2):137-143. doi: 10.1016/j.annpat.2019.01.017. Epub 2019 Feb 25. Review. French.

PMID:
30819623
25.

Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.

Blons H, Garinet S, Laurent-Puig P, Oudart JB.

J Thorac Dis. 2019 Jan;11(Suppl 1):S25-S36. doi: 10.21037/jtd.2018.12.48. Review.

26.

Meeting report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer.

Gunter MJ, Alhomoud S, Arnold M, Brenner H, Burn J, Casey G, Chan AT, Cross AJ, Giovannucci E, Hoover R, Houlston R, Jenkins M, Laurent-Puig P, Peters U, Ransohoff D, Riboli E, Sinha R, Stadler ZK, Brennan P, Chanock SJ.

Ann Oncol. 2019 Apr 1;30(4):510-519. doi: 10.1093/annonc/mdz044.

27.

Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.

Mansuet-Lupo A, Barritault M, Alifano M, Janet-Vendroux A, Zarmaev M, Biton J, Velut Y, Le Hay C, Cremer I, Régnard JF, Fournel L, Rance B, Wislez M, Laurent-Puig P, Herbst R, Damotte D, Blons H.

J Thorac Oncol. 2019 May;14(5):844-856. doi: 10.1016/j.jtho.2019.01.017. Epub 2019 Feb 2.

PMID:
30721797
28.

Circadian genes and risk of prostate cancer: Findings from the EPICAP study.

Wendeu-Foyet MG, Koudou Y, Cénée S, Trétarre B, Rébillard X, Cancel-Tassin G, Cussenot O, Boland A, Bacq D, Deleuze JF, Lamy PJ, Mulot C, Laurent-Puig P, Truong T, Menegaux F.

Int J Cancer. 2019 Oct 1;145(7):1745-1753. doi: 10.1002/ijc.32149. Epub 2019 Feb 12.

PMID:
30665264
29.

Systemic treatment of pancreatic cancer revisited.

Ducreux M, Seufferlein T, Van Laethem JL, Laurent-Puig P, Smolenschi C, Malka D, Boige V, Hollebecque A, Conroy T.

Semin Oncol. 2019 Feb;46(1):28-38. doi: 10.1053/j.seminoncol.2018.12.003. Epub 2018 Dec 27. Review.

30.

Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options.

Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranel J, Blons H, Goldwasser F, Laurent-Puig P.

J Med Genet. 2020 Feb;57(2):104-108. doi: 10.1136/jmedgenet-2018-105594. Epub 2018 Oct 23.

PMID:
30352869
31.

[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]

Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M.

Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Review. French.

PMID:
30343945
32.

Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: A gene-set analysis.

Berrandou T, Mulot C, Cordina-Duverger E, Arveux P, Laurent-Puig P, Truong T, Guénel P.

Int J Cancer. 2019 Apr 15;144(8):1896-1908. doi: 10.1002/ijc.31917. Epub 2018 Dec 14.

PMID:
30303517
33.

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J, Franchimont D, Verset L, Galdon MG, Devière J, de Reyniès A, Laurent-Puig P, Van Laethem JL, Bachet JB, Maréchal R.

Gastroenterology. 2018 Dec;155(6):1999-2013.e3. doi: 10.1053/j.gastro.2018.08.033. Epub 2018 Aug 27.

PMID:
30165049
34.

Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights.

Cohen R, Sroussi M, Pilati C, Houry S, Laurent-Puig P, André T.

J Gastrointest Oncol. 2018 Aug;9(4):E23-E27. doi: 10.21037/jgo.2018.05.10.

35.

Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity.

Uchuya-Castillo J, Aznar N, Frau C, Martinez P, Le Nevé C, Marisa L, Penalva LOF, Laurent-Puig P, Puisieux A, Scoazec JY, Samarut J, Ansieau S, Plateroti M.

Oncotarget. 2018 Jul 24;9(57):30979-30996. doi: 10.18632/oncotarget.25741. eCollection 2018 Jul 24.

36.

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Touat M, Gratieux J, Condette Auliac S, Sejean K, Aldea S, Savatovsky J, Perkins G, Blons H, Ligon KL, Idbaih A, Hollebecque A, Gimenez-Roqueplo AP, Laurent-Puig P, Sanson M, Villa C, Di Stefano AL.

Neurology. 2018 Sep 11;91(11):523-525. doi: 10.1212/WNL.0000000000006171. Epub 2018 Aug 17. No abstract available.

PMID:
30120137
37.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

Vaughn CP, Costa JL, Feilotter HE, Petraroli R, Bagai V, Rachiglio AM, Marino FZ, Tops B, Kurth HM, Sakai K, Mafficini A, Bastien RRL, Reiman A, Le Corre D, Boag A, Crocker S, Bihl M, Hirschmann A, Scarpa A, Machado JC, Blons H, Sheils O, Bramlett K, Ligtenberg MJL, Cree IA, Normanno N, Nishio K, Laurent-Puig P.

BMC Cancer. 2018 Aug 16;18(1):828. doi: 10.1186/s12885-018-4736-4.

38.

Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.

Laurent-Puig P, Grisoni ML, Heinemann V, Liebaert F, Neureiter D, Jung A, Montestruc F, Gaston-Mathe Y, Thiébaut R, Stintzing S.

Clin Cancer Res. 2019 Jan 1;25(1):134-141. doi: 10.1158/1078-0432.CCR-18-1324. Epub 2018 Aug 14.

39.

Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' reply.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 Sep;50(9):974-975. doi: 10.1016/j.dld.2018.06.014. Epub 2018 Jun 28. No abstract available.

40.

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.

Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P; PETACC8 investigators.

Clin Cancer Res. 2018 Oct 1;24(19):4745-4753. doi: 10.1158/1078-0432.CCR-18-0866. Epub 2018 Jun 19.

41.

Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?

Garinet S, Laurent-Puig P, Blons H, Oudart JB.

J Clin Med. 2018 Jun 9;7(6). pii: E144. doi: 10.3390/jcm7060144. Review.

42.

Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation.

Leclerc J, Flament C, Lovecchio T, Delattre L, Ait Yahya E, Baert-Desurmont S, Burnichon N, Bronner M, Cabaret O, Lejeune S, Guimbaud R, Morin G, Mauillon J, Jonveaux P, Laurent-Puig P, Frébourg T, Porchet N, Buisine MP.

Genet Med. 2018 Dec;20(12):1589-1599. doi: 10.1038/gim.2018.47. Epub 2018 Apr 12.

PMID:
29790873
43.

Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer: Results of a 2-Year Experience on 1343 Samples.

Legras A, Barritault M, Tallet A, Fabre E, Guyard A, Rance B, Digan W, Pecuchet N, Giroux-Leprieur E, Julie C, Jouveshomme S, Duchatelle V, Giraudet V, Gibault L, Cazier A, Pastre J, Le Pimpec-Barthes F, Laurent-Puig P, Blons H.

J Mol Diagn. 2018 Jul;20(4):550-564. doi: 10.1016/j.jmoldx.2018.04.002. Epub 2018 May 19.

44.

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.

Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D.

Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15.

45.

Role of circulating tumor DNA in the management of patients with colorectal cancer.

Moati E, Taly V, Didelot A, Perkins G, Blons H, Taieb J, Laurent-Puig P, Zaanan A.

Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):396-402. doi: 10.1016/j.clinre.2018.03.002. Epub 2018 Apr 5. Review.

PMID:
29627453
46.

Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients.

Boeckx N, Op de Beeck K, Beyens M, Deschoolmeester V, Hermans C, De Clercq P, Garrigou S, Normand C, Monsaert E, Papadimitriou K, Laurent-Puig P, Pauwels P, Van Camp G, Taly V, Peeters M.

Clin Colorectal Cancer. 2018 Jun;17(2):e369-e379. doi: 10.1016/j.clcc.2018.02.006. Epub 2018 Feb 22.

PMID:
29605591
47.

BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/μL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA.

Andriamanampisoa CL, Bancaud A, Boutonnet-Rodat A, Didelot A, Fabre J, Fina F, Garlan F, Garrigou S, Gaudy C, Ginot F, Henaff D, Laurent-Puig P, Morin A, Picot V, Saias L, Taly V, Tomasini P, Zaanan A.

Anal Chem. 2018 Mar 20;90(6):3766-3774. doi: 10.1021/acs.analchem.7b04034. Epub 2018 Mar 9.

PMID:
29498256
48.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P.

Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.

49.

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

Zaanan A, Samalin E, Aparicio T, Bouche O, Laurent-Puig P, Manfredi S, Michel P, Monterymard C, Moreau M, Rougier P, Tougeron D, Taieb J, Louvet C.

Dig Liver Dis. 2018 Apr;50(4):408-410. doi: 10.1016/j.dld.2018.01.119. Epub 2018 Mar 1.

PMID:
29409778
50.

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza RA, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 May;50(5):507-512. doi: 10.1016/j.dld.2017.12.029. Epub 2018 Jan 8.

Supplemental Content

Loading ...
Support Center